Family Screening with NeuroScreen

Whether you are concerned about familial risk, post-COVID neurological symptoms, or simply want to optimise your brain health, NeuroScreen provides the most comprehensive approach to neurological screening available today.

What is the NeuroScreen?

NeuroScreen is a screening tool designed to detect subtle early signs of neurodegenerative diseases and assess familial risk factors. Early detection allows for timely intervention, and awareness of potential risks can lead to preventive strategies that safeguard brain function and long-term well-being.

The Power of Early Detection

At Sanctura, our NeuroScreen tool allows patients to understand their neurological health at the deepest level. By identifying early signs of neurodegenerative diseases and understanding risk factors, patients can make informed decisions about their health, implement preventive strategies, and seek interventions at the earliest possible stage.

We combine the latest medical technology with in-depth health assessments to empower individuals to take control of their neurological health.

biofeedback-eeg-electroencephalograph-training-health-center

Sanctura Oncology TreatmentNeuro Risk Questionnaire

The first step in the NeuroScreen process is a holistic assessment through a questionnaire. This questionnaire gives patients a clear picture of potential risk factors and informs the subsequent screening phases. It includes:
Sanctura Oncology Treatment

Familial history of diseases such as Alzheimer's, Parkinson's, and multiple sclerosis.

Sanctura Oncology Treatment

Lifestyle factors such as diet, exercise, smoking, alcohol use, and exposure to toxins.

Sanctura Oncology Treatment

Other associated health conditions, including diabetes, hypertension, cardiovascular disease, and chronic infections.

Sanctura Oncology Treatment

Neurocognitive performance metrics to evaluate memory, problem-solving, and motor coordination.

Sanctura Oncology TreatmentHereditary Gene Panel

Our Neuro-Hereditary Gene Panel screens for all known genetic factors associated with neurodegenerative diseases. This genetic information gives us insights into familial risks, so we can develop tailored prevention strategies and initiate personalised health interventions.

Using advanced genomic technologies, our Neuro-Hereditary Gene Panel tests for mutations and variations in genes that predispose individuals to:
Sanctura Oncology Treatment

Alzheimer's disease

Sanctura Oncology Treatment

Vascular dementia

Sanctura Oncology Treatment

Parkinson's disease

Sanctura Oncology Treatment

Multiple sclerosis (MS)

Sanctura Oncology Treatment

Other hereditary neurodegenerative conditions

Sanctura Oncology TreatmentAdvanced MRI Screening

We use the latest MRI technology to scan the brain for early indicators of neurodegenerative diseases, such as brain atrophy, vascular dementia, and autoimmune-related neurological damage. This detailed imaging assesses:
Sanctura Oncology Treatment

Blood flow and microvasculature of the brain to detect any issues in circulation.

Sanctura Oncology Treatment

Early neurological lesions and atrophy associated with conditions like Alzheimer's and Parkinson’s.

Sanctura Oncology Treatment

Reduction in myelin sheaths, which can signify the early stages of multiple sclerosis.

Sanctura Oncology Treatment

Hyperperfused areas or regions with abnormal blood supply, indicative of neurodegenerative changes or inflammatory processes.

Sanctura Oncology Treatment

Post-COVID neurological conditions and autoimmune triggers that can impact the brain.

Sanctura Oncology TreatmentBlood Work & Immune Profile

A full blood panel is conducted to identify inflammatory markers and other indicators of potential neurological issues. These tests provide a complete picture of the patient’s biochemical health and can highlight potential neurological risk factors that warrant further investigation or intervention.

This includes:
Sanctura Oncology Treatment

Inflammatory markers that may signal underlying conditions affecting the brain, nerves, or blood vessels.

Sanctura Oncology Treatment

Immune profile to detect imbalances that predispose individuals to autoimmune diseases or chronic infections.

Sanctura Oncology Treatment

Screening for micronutrient deficiencies essential for nerve and vascular health, such as zinc, selenium, magnesium, and iron saturation.

Sanctura Oncology Treatment

Methylation cofactors like B vitamins, folic acid, and homocysteine to support brain synapse and vascular health.

Sanctura Oncology Treatment

Cholesterol levels and endocrine function, with a focus on thyroid hormones, testosterone, and oestrogen.

Sanctura Oncology TreatmentNeurofeedback Analysis

Our Neurofeedback system uses quantitative EEG (qEEG) measurements to assess brainwave patterns and identify areas of possible neurological dysfunction. Once we detect abnormal brainwave patterns, we can target neurofeedback therapy to improve cognitive function.

This is particularly helpful for:
Sanctura Oncology Treatment

Traumatic brain injuries that have caused cognitive impairment or axonal shifts.

Sanctura Oncology Treatment

Stress-induced glutamate excitotoxicity, where prolonged stress damages neurons.

Sanctura Oncology Treatment

Sluggish brainwave activity, indicating cognitive decline or underperformance in certain brain regions.

Sanctura Oncology TreatmentSpecialised Tests: DAT Scan, Functional MRI, and Peripheral Nerve Studies

For more in-depth assessment, specialised neurological tests may be required. These additional screenings offer advanced diagnostic capabilities to make sure no potential neurological issue goes undetected.

These tests include:
Sanctura Oncology Treatment

DAT scans, which evaluate dopamine activity in the brain and help diagnose Parkinson’s disease.

Sanctura Oncology Treatment

Functional MRI (fMRI) to assess brain activity in real time, providing a deeper understanding of brain function and potential areas of concern.

Sanctura Oncology Treatment

Peripheral nerve studies are used to identify nerve damage that may contribute to cognitive or motor impairments.